Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.33
- Piotroski Score 4.00
- Grade Buy
- Symbol (PSNL)
- Company Personalis, Inc.
- Price $3.38
- Changes Percentage (-2.31%)
- Change -$0.08
- Day Low $3.29
- Day High $3.50
- Year High $7.20
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $7.50
- High Stock Price Target $13.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.90
- Trailing P/E Ratio -0.71
- Forward P/E Ratio -0.71
- P/E Growth -0.71
- Net Income $-108,296,000
Income Statement
Quarterly
Annual
Latest News of PSNL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Even after rising 48% this past week, Personalis (NASDAQ:PSNL) shareholders are still down 89% over the past three years
Personalis Inc. (NASDAQ: PSNL) shares surged 94% this month after a significant 89% decline in the last three years. While recent signs of promise are evident, the company's revenue decline of 6.7% an...
By Yahoo! Finance | 4 months ago
